142 related articles for article (PubMed ID: 8034071)
1. Prolonged opioid blockade with naltrexone and luteinizing hormone modifications in women with polycystic ovarian syndrome.
Cagnacci A; Soldani R; Paoletti AM; Falqui A; Melis GB
Fertil Steril; 1994 Aug; 62(2):269-72. PubMed ID: 8034071
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study.
Fulghesu AM; Ciampelli M; Belosi C; Apa R; Guido M; Caruso A; Mancuso S; Lanzone A
J Endocrinol Invest; 2001; 24(7):483-90. PubMed ID: 11508781
[TBL] [Abstract][Full Text] [Related]
3. Prolonged opioid blockade does not influence luteinizing hormone modifications of the follicular and luteal menstrual phases.
Cagnacci A; Paoletti AM; Soldani R; Tuveri F; Melis GB
J Clin Endocrinol Metab; 1995 Mar; 80(3):860-3. PubMed ID: 7883843
[TBL] [Abstract][Full Text] [Related]
4. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion.
Lanzone A; Fulghesu AM; Cucinelli F; Ciampelli M; Caruso A; Mancuso S
J Clin Endocrinol Metab; 1995 Dec; 80(12):3501-6. PubMed ID: 8530590
[TBL] [Abstract][Full Text] [Related]
5. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome.
Patel K; Coffler MS; Dahan MH; Malcom PJ; Deutsch R; Chang RJ
Clin Endocrinol (Oxf); 2004 Jan; 60(1):67-74. PubMed ID: 14678290
[TBL] [Abstract][Full Text] [Related]
6. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
Hayes FJ; Taylor AE; Martin KA; Hall JE
J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
[TBL] [Abstract][Full Text] [Related]
7. Effects of dexamethasone and dexamethasone plus naltrexone on pituitary response to GnRH and TRH in normal women.
la Marca A; Torricelli M; Morgante G; Lanzetta D; De Leo V
Horm Res; 1999; 51(2):85-90. PubMed ID: 10352398
[TBL] [Abstract][Full Text] [Related]
8. Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome.
Lanzone A; Apa R; Fulghesu AM; Cutillo G; Caruso A; Mancuso S
Fertil Steril; 1993 Apr; 59(4):734-7. PubMed ID: 8458488
[TBL] [Abstract][Full Text] [Related]
9. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
10. Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea.
Couzinet B; Young J; Brailly S; Chanson P; Schaison G
J Clin Endocrinol Metab; 1995 Jul; 80(7):2102-7. PubMed ID: 7608262
[TBL] [Abstract][Full Text] [Related]
11. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
Arroyo A; Laughlin GA; Morales AJ; Yen SS
J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
[TBL] [Abstract][Full Text] [Related]
12. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Pastor CL; Griffin-Korf ML; Aloi JA; Evans WS; Marshall JC
J Clin Endocrinol Metab; 1998 Feb; 83(2):582-90. PubMed ID: 9467578
[TBL] [Abstract][Full Text] [Related]
14. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
[TBL] [Abstract][Full Text] [Related]
15. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
Cheung AP; Lu JK; Chang RJ
Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine control in polycystic ovary-like syndrome.
Schoemaker J
Gynecol Endocrinol; 1991 Dec; 5(4):277-88. PubMed ID: 1796749
[TBL] [Abstract][Full Text] [Related]
18. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
McCartney CR; Eagleson CA; Marshall JC
Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
[TBL] [Abstract][Full Text] [Related]
19. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients.
Moret M; Stettler R; Rodieux F; Gaillard RC; Waeber G; Wirthner D; Giusti V; Tappy L; Pralong FP
Neuroendocrinology; 2009; 89(2):131-9. PubMed ID: 18832802
[TBL] [Abstract][Full Text] [Related]
20. Endogenous opiates modulate the pulsatile secretion of biologically active luteinizing hormone in man.
Veldhuis JD; Rogol AD; Johnson ML
J Clin Invest; 1983 Dec; 72(6):2031-40. PubMed ID: 6315775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
